Sana Biotechnology, Inc. (SANA)
After hours:
| Previous Close | 7.93 |
| Open | 8.00 |
| Bid | 8.07 x 1200 |
| Ask | 8.14 x 100 |
| Day's Range | 7.90 - 8.33 |
| 52 Week Range | 2.74 - 12.00 |
| Volume | |
| Avg. Volume | 2,014,861 |
| Market Cap | 1.783B |
| Beta (5Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.17 |
GuruFocus.comDirector Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA)
Director Patrick Yang has sold 25,000 shares of Sana Biotechnology Inc (NASDAQ:SANA), according to a recent SEC Filing.
GuruFocus.comBaillie Gifford Bolsters Stake in Sana Biotechnology Inc
Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently expanded its investment portfolio by adding a significant number of shares in Sana Biotechnology Inc (NASDAQ:SANA). This move underscores the firm's confidence in the biotechnology company's growth potential. On February 1, 2024, Baillie Gifford (Trades, Portfolio) acquired an additional 210,603 shares of Sana Biotechnology, reflecting a 2.07% change in their holdings and bringing the total shares owned to 10,360,620.
GlobeNewswireSana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory NHL and CLL suggest ability to dose safely, demonstrate the desired immune evasion profile, and early clinical efficacy using hypoimmune technology Announced SC291 IND clearance for B-cell mediated autoimmune diseases with goal to report initial clinical data in 2024 Announced SC262 IND
